Sickle cell disease

sickle-cell

← back to Hematology & Oncology

Summary

ASH 2019 guidelines on cardiopulmonary and kidney disease in sickle cell disease (SCD) address screening and management of pulmonary hypertension, sleep-disordered breathing, abnormal pulmonary function, venous thromboembolism, albuminuria, and chronic kidney disease. The panel generally recommends against routine screening of asymptomatic patients with echocardiography, polysomnography, or pulmonary function testing, favoring targeted evaluation based on signs and symptoms. Recommendations also address anticoagulation duration for VTE, ACEi/ARB use for albuminuria, renal transplant referral, and combined hydroxyurea plus erythropoiesis-stimulating agent therapy for CKD-related anemia.

Current guideline: ASH 2014–2020 Sickle Cell Disease Guideline Series · download Anki sub-deck

Versions

  • 2020 · ASH — ASH 2014–2020 Sickle Cell Disease Guideline Series
    • Pocket-guide series. Primary file (Cardiopulmonary & Kidney Disease) at source.pdf.local. Companion pocket guides in same folder: 2020-ash-chronic-complications.pdf, 2020-ash-hydroxyurea.pdf, 2020-ash-transfusion.pdf.
    • Read the guideline: html · Anki deck
  • 2014 · NHLBI — NHLBI 2014 SCD Guideline

Table of contents